Drugnews｜藥時事

Official Site

Drugnews｜Biotech Business Analysis

Drugnews turns clinical data, company strategy, licensing activity, and capital-market signals into clear business judgment for biotech and pharmaceutical readers.

37,000+Facebook followers across Taiwan's biotech investment and business-analysis community.
Latest English Articles Company Services Paid Research Research Guides Chinese Archive
AI drug development clinical asset engine cover
FeaturedBusiness Analysis

The Next Phase of AI Drug Development: Making Molecules Survive as Drugs

AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.

Read the article

Editorial Focus

From science to market judgment.

We cover company research, clinical and CMC risks, licensing and BD, valuation, and capital-market signals. The goal is not to summarize news, but to explain which evidence can change business value.